500126 Stock Overview
Engages in the manufacture and marketing of pharmaceuticals and chemical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Procter & Gamble Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹5,233.15 |
| 52 Week High | ₹5,640.00 |
| 52 Week Low | ₹4,640.30 |
| Beta | 0.54 |
| 11 Month Change | 5.22% |
| 3 Month Change | 10.77% |
| 1 Year Change | -1.36% |
| 33 Year Change | -2.30% |
| 5 Year Change | 10.36% |
| Change since IPO | 127,227.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500126 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.1% | 2.2% | -1.0% |
| 1Y | -1.4% | 46.7% | 43.6% |
Return vs Industry: 500126 underperformed the Indian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: 500126 underperformed the Indian Market which returned 43.6% over the past year.
Price Volatility
| 500126 volatility | |
|---|---|
| 500126 Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.7% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 500126 has not had significant price volatility in the past 3 months.
Volatility Over Time: 500126's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 1,407 | Milind Thatte | www.pghealthindia.com |
Procter & Gamble Health Limited engages in the manufacture and marketing of pharmaceuticals and chemical products in India and internationally. The company provides over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Cosome, Polybion, Neurobion, Evion, Nasivion, Livogen, and Seven Seas brands.
Procter & Gamble Health Limited Fundamentals Summary
| 500126 fundamental statistics | |
|---|---|
| Market cap | ₹86.87b |
| Earnings (TTM) | ₹2.14b |
| Revenue (TTM) | ₹11.69b |
40.6x
P/E Ratio7.4x
P/S RatioIs 500126 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500126 income statement (TTM) | |
|---|---|
| Revenue | ₹11.69b |
| Cost of Revenue | ₹3.67b |
| Gross Profit | ₹8.02b |
| Other Expenses | ₹5.88b |
| Earnings | ₹2.14b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | 128.93 |
| Gross Margin | 68.61% |
| Net Profit Margin | 18.31% |
| Debt/Equity Ratio | 1.3% |
How did 500126 perform over the long term?
See historical performance and comparison